Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.
Tolmeijer SH, Boerrigter E, Sumiyoshi T, Kwan EM, Ng SWS, Annala M, Donnellan G, Herberts C, Benoist GE, Hamberg P, Somford DM, van Oort IM, Schalken JA, Mehra N, van Erp NP, Wyatt AW.
Tolmeijer SH, et al. Among authors: van oort im, van erp np.
Clin Cancer Res. 2023 Aug 1;29(15):2835-2844. doi: 10.1158/1078-0432.CCR-22-2998.
Clin Cancer Res. 2023.
PMID: 36996325